Vous n'êtes pas identifié (connexion)

Centre de recherche

JEUDI 04 MAI

Dr Nicholas Brousseau et Dre Marie-France Beaudet, Direction de la Santé publique

Séminaire

Les oreillons; toujours d'actualité en 2017

Calendrier >

BOTTIN

Isabelle Laverdière

Formation
à venir

Aucune offre active

Autres opportunités de carrière
Axe principal
Oncologie
Adresse(s)
Centre Hospitalier de l'Université Laval (CHUL)
2705, boulevard Laurier
R-4715
Québec (Québec)
CANADA G1V 4G2

Téléphone(s)
+1 418-525-4444, poste 48670
Télécopieur(s)
+1 418-654-2298
Courriel(s)
Isabelle.Laverdiere@crchudequebec.ulaval.ca

Projet(s) de recherche actif(s)

Aucun projet de recherche à afficher

Publications récentes (voir toutes les publications de ce chercheur)

Laverdiere I, Boileau M, Herold T, Rak J, Berdel WE, Wormann B, Hiddemann W, Spiekermann K, Bohlander SK, Eppert K. Complement cascade gene expression defines novel prognostic subgroups of acute myeloid leukemia. Experimental hematology,  2016. 44: 1039-1043.e10
Laverdiere I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socie G, Levesque E. Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica,  2015. 100: 275-83
Chen S, Villeneuve L, Jonker D, Couture F, Laverdiere I, Cecchin E, Innocenti F, Toffoli G, Levesque E, Guillemette C. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and genomics,  2015. 25: 573-83
Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Levesque E, Guillemette C. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. The pharmacogenomics journal,  2015. Epub
Laverdiere I, Flageole C, Audet-Walsh E, Caron P, Fradet Y, Lacombe L, Levesque E, Guillemette C. The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-related cancer,  2015. 22: 77-85
Levesque E, Laverdiere I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C. Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway. Clinical cancer research : an official journal of the American Association for Cancer Research,  2014. 20: 2971-83
Levesque E, Laverdiere I, Lacombe L, Caron P, Rouleau M, Turcotte V, Tetu B, Fradet Y, Guillemette C. Importance of 5alpha-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research,  2014. 20: 576-84
Huang SP, Levesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdiere I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. International journal of cancer. Journal international du cancer,  2014. 135: 2661-7
Levesque E, Huang SP, Audet-Walsh E, Lacombe L, Bao BY, Fradet Y, Laverdiere I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C. Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression. Clinical cancer research : an official journal of the American Association for Cancer Research,  2013. 19: 699-709
Laverdiere I, Caron P, Couture F, Levesque E, Guillemette C. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences ,  2012. 885-886: 131-7
© 2017 Tous droits réservés Centre de recherche du CHU de Québec